A more recent strategy involves an advanced ADC that targets EGFR on the tumor cell surface while delivering a CDK inhibitor to disrupt dysregulated cell cycle signaling, offering a potential treatment option for patients with EGFR-expressing, therapy-resistant triple-negative breast cancer (TNBC) [31]. The gene discussed is EGFR; the disease is neoplasm.